Donnez J, Taylor HS, Taylor RN, et al. - Researchers examined how a new investigational oral gonadotropin-releasing hormone antagonist, linzagolix, affects endometriosis-associated pain (EAP) via performing a multinational, parallel group, randomized, placebo-controlled, double-blind, dose-ranging trial. Women aged 18–45 years with surgically confirmed endometriosis and moderate-to-severe EAP were administered 50, 75, 100, or 200 mg linzagolix (or matching placebo) once daily for 24 weeks. Outcomes revealed significantly reduced EAP and improved quality of life in correlation with receiving linzagolix at doses of 75–200 mg. Further, linzagolix led to dose-dependent decrease in bone mineral density.